Natera, Inc. (NTRA)
- Previous Close
88.61 - Open
89.44 - Bid 91.81 x 100
- Ask 91.92 x 100
- Day's Range
89.44 - 93.05 - 52 Week Range
36.90 - 98.82 - Volume
694,449 - Avg. Volume
1,423,095 - Market Cap (intraday)
11.084B - Beta (5Y Monthly) 1.39
- PE Ratio (TTM)
-- - EPS (TTM)
-3.78 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
103.94
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.
www.natera.com3,282
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NTRA
Performance Overview: NTRA
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NTRA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NTRA
Valuation Measures
Market Cap
10.70B
Enterprise Value
10.26B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.41
Price/Book (mrq)
13.98
Enterprise Value/Revenue
9.48
Enterprise Value/EBITDA
-25.80
Financial Highlights
Profitability and Income Statement
Profit Margin
-40.16%
Return on Assets (ttm)
-19.67%
Return on Equity (ttm)
-59.11%
Revenue (ttm)
1.08B
Net Income Avi to Common (ttm)
-434.8M
Diluted EPS (ttm)
-3.78
Balance Sheet and Cash Flow
Total Cash (mrq)
878.98M
Total Debt/Equity (mrq)
57.75%
Levered Free Cash Flow (ttm)
-183.1M